title: [An exploration of the expression of MK and MVD in cervical cancer tissues before and after NACT].
abstract: OBJECTIVE
  To investigate the clinical effect of neoadjuvant chemotherapy (NACT) and its influence on the expressions of MK and MVD in cervical cancer cells.
  
  
  METHODS
  The expressions of MK, CD34 were determined by immunohistochemistry in 35 cases of cervical cancer before and after NACT.
  
  
  RESULTS
  Among the 35 cases treated with NACT, 4 (11.43%) were complete remission (CR), 25 (71.43%) partial remission (PR). The total effective rate of NACT (CR+PR) was 82.86%. The expressions of MK and MVD decreased dramatically after NACT. In cases who reacted positively to NACT, the expression of MK and the level of MVD decreased significantly after the treatment (P<0.05). While in cases who reacted poorly to NACT no such changes were observed in the expression of MK (P>0.05); but the level of MVD also decreased in those cases.
  
  
  CONCLUSIONS
  NACT is an effective treatment for cervical cancer. The expressions of MK and MVD decreased after NACT treatment. It implied that one of the mechanisms of NACT may be the suppression of angiogenesis, and the expression of MK may serve as an indicator for predicting the therapeutic effect of NACT.
authors.affiliation: Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: Ai
authors.initials: A
authors.lastname: Zheng
authors.forename: Dan
authors.initials: D
authors.lastname: Chai
authors.forename: Yan-xia
authors.initials: YX
authors.lastname: Chu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000378:metabolism / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage; D016207:Cytokines / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D055806:Microvessels / Q000473:pathology; D008875:Middle Aged; D000078792:Midkine; D020360:Neoadjuvant Therapy / Q000379:methods*; D009389:Neovascularization, Pathologic / Q000473:pathology*; D002583:Uterine Cervical Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000628:therapy*; D055815:Young Adult
chemical_list: D016207:Cytokines; D001761:Bleomycin; D000078792:Midkine; C025703:bleomycetin; D002945:Cisplatin